|Bid||141.50 x 20000|
|Ask||141.80 x 20000|
|Day's Range||141.60 - 141.60|
|52 Week Range||128.22 - 200.25|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||12.66|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cigna's stock down after forecasting full year revenue below analysts' expectations. The company also facing the possibility of of the U.S. government ending rebates that it says are to blame for high drug prices. Yahoo Finance's Jackie DeAngelis and Brian Cheung discuss.
To CVS Health CVS and Cigna we now assign positive trend ratings, largely attributable to the competitive benefits we expect these businesses to achieve through their integrations of Aetna and Express Scripts, respectively. Unrivaled scale allows UnitedHealth to price its insurance book commensurate with the lowest cost per insured member of the companies we cover, which has led to industry-leading gains in membership over the past five years.
Cigna CEO David Cordani doesn't see the Trump administration's new proposal to cut Medicare pharmacy benefit rebates as a threat to its growth, as it embarks on integrating its newly acquired PBM firm Express Scripts.
The U.S. government's proposal to eliminate rebates that pharmacy benefit managers receive from drugmakers will not have a meaningful impact on growth, and does not affect the commercial market, Cigna Corp Chief Executive Officer David Cordani said on Friday. Investors are worried that Cigna, which closed its $52 billion acquisition of PBM Express Scripts in December, could be hurt by the Trump administration's proposal targeting after-market discounts that middlemen in the pharmaceutical supply chain have received for decades.
"The proposed rebate rule will not have a meaningful impact on our growth or earnings trajectory," Cordani said on a conference call with analysts. The U.S. government on Thursday proposed a rule to end a decades-old system of after-market discounts called rebates that pharmacy benefit managers receive from drugmakers, a potential blow to companies like Cigna's Express Scripts, which act as middlemen in the pharmaceuticals supply chain.
Check out the companies making headlines before the bell: Merck MRK – Merck earned an adjusted $1.04 per share for the fourth quarter, beating estimates by a penny a share. Revenue came in very slightly above Wall Street forecasts.
The Bloomfield, Connecticut-based company said it had profit of 55 cents per share. Earnings, adjusted for non-recurring costs, came to $2.46 per share. The results missed Wall Street expectations. The ...
Cigna Corp reported a 34.5 percent rise in quarterly revenue, helped by higher enrollment in the first quarter since it closed its acquisition of pharmacy benefits manager Express Scripts. Cigna's net ...
The Trump administration's new proposals would ban what it calls "backdoor rebates," as it seeks to lower drug costs for consumers at the pharmacy counter. The administration says those confidential rebates have led to a "perverse incentive" for drug makers to make list prices on drugs artificially high. HHS Secretary Alex Azar says in a statement that the goal would be to create a system that prioritizes savings for patients.
After strong earnings from aircraft manufacturing behemoth Boeing Co. propelled the U.S. market higher Wednesday, stocks were mixed Thursday. The Dow Jones Industrial Average fell more than 50 points Thursday afternoon, giving back some of its gains Wednesday.
Cigna (NYSE: CI ) unveils its next round of earnings this Friday, Feb. 1. Get prepared with Benzinga's ultimate preview for Cigna's Q4 earnings. Earnings and Revenue Analysts predict Cigna will report ...
Anthem stock vaulted higher, touching a buy point intraday, after the company issued a far-better-than-expected profit forecast this year.